From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: A 6-month, multicenter, open-label tolerability switch study

Gemma Caterina Maria Rossi, Gian Maria Pasinetti, Francesco Sandolo, Marco Bordin, Paolo Emilio Bianchi

Research output: Contribution to journalArticle

Abstract

Purpose: To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). Methods: Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pressure (IOP), tear film break-up-time (TF-BUT), fluorescein staining and Glaucoma Symptom Scale (GSS) questionnaire were recorded at baseline and after 6 months. Results: Median interquartile range (IQR) IOP was 16 (IQR 15 18) mmHg at baseline and 16 (15 17) mmHg and 6 months. TF-BUT significantly improved (p <0.0001); the regression analysis found a negative association between TF-BUT changes and age at baseline and at month 6 (r = -0.32; p = 0.0082 and r = -0.31; p = 0.0085). Patients with no corneal fluorescein staining statistically increased after substitution (p = 0.04). Quality of life as examined by the GSS symptoms (SYMP) score statistically improved (p <0.0001), revealing an association between GSS SYMP score and age [coefficient -0.67, 95% confidence interval (CI) -1.13 to -0.21, p = 0.0005), superficial keratitis (coefficient -8.26, 95% CI -15.73 to -0.80, p = 0.031) and TF-BUT (coefficient 4.94, 95% CI 1.71 to 8.17, p = 0.003). Conclusion: Brinzolamide/timolol FC is associated with reduced topical discomfort and improved signs of ocular surface disease. The good tolerability and comfort of this FC might contribute to good patient adherence.

Original languageEnglish
Pages (from-to)2425-2431
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number16
DOIs
Publication statusPublished - Nov 2011

Fingerprint

dorzolamide
Timolol
Tears
Glaucoma
Confidence Intervals
Fluorescein
Intraocular Pressure
Staining and Labeling
Eye Diseases
Keratitis
Patient Compliance
Regression Analysis
Quality of Life
brinzolamide
Prospective Studies

Keywords

  • brinzolamide/timolol fixed combination
  • efficacy
  • glaucoma
  • ocular surface
  • tolerability

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination : A 6-month, multicenter, open-label tolerability switch study. / Rossi, Gemma Caterina Maria; Pasinetti, Gian Maria; Sandolo, Francesco; Bordin, Marco; Bianchi, Paolo Emilio.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 16, 11.2011, p. 2425-2431.

Research output: Contribution to journalArticle

@article{1a3075692c8d4ae4b38d787d540b5ea0,
title = "From dorzolamide 2{\%}/timolol 0.5{\%} to brinzolamide 1{\%}/timolol 0.5{\%} fixed combination: A 6-month, multicenter, open-label tolerability switch study",
abstract = "Purpose: To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). Methods: Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pressure (IOP), tear film break-up-time (TF-BUT), fluorescein staining and Glaucoma Symptom Scale (GSS) questionnaire were recorded at baseline and after 6 months. Results: Median interquartile range (IQR) IOP was 16 (IQR 15 18) mmHg at baseline and 16 (15 17) mmHg and 6 months. TF-BUT significantly improved (p <0.0001); the regression analysis found a negative association between TF-BUT changes and age at baseline and at month 6 (r = -0.32; p = 0.0082 and r = -0.31; p = 0.0085). Patients with no corneal fluorescein staining statistically increased after substitution (p = 0.04). Quality of life as examined by the GSS symptoms (SYMP) score statistically improved (p <0.0001), revealing an association between GSS SYMP score and age [coefficient -0.67, 95{\%} confidence interval (CI) -1.13 to -0.21, p = 0.0005), superficial keratitis (coefficient -8.26, 95{\%} CI -15.73 to -0.80, p = 0.031) and TF-BUT (coefficient 4.94, 95{\%} CI 1.71 to 8.17, p = 0.003). Conclusion: Brinzolamide/timolol FC is associated with reduced topical discomfort and improved signs of ocular surface disease. The good tolerability and comfort of this FC might contribute to good patient adherence.",
keywords = "brinzolamide/timolol fixed combination, efficacy, glaucoma, ocular surface, tolerability",
author = "Rossi, {Gemma Caterina Maria} and Pasinetti, {Gian Maria} and Francesco Sandolo and Marco Bordin and Bianchi, {Paolo Emilio}",
year = "2011",
month = "11",
doi = "10.1517/14656566.2011.589384",
language = "English",
volume = "12",
pages = "2425--2431",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "16",

}

TY - JOUR

T1 - From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination

T2 - A 6-month, multicenter, open-label tolerability switch study

AU - Rossi, Gemma Caterina Maria

AU - Pasinetti, Gian Maria

AU - Sandolo, Francesco

AU - Bordin, Marco

AU - Bianchi, Paolo Emilio

PY - 2011/11

Y1 - 2011/11

N2 - Purpose: To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). Methods: Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pressure (IOP), tear film break-up-time (TF-BUT), fluorescein staining and Glaucoma Symptom Scale (GSS) questionnaire were recorded at baseline and after 6 months. Results: Median interquartile range (IQR) IOP was 16 (IQR 15 18) mmHg at baseline and 16 (15 17) mmHg and 6 months. TF-BUT significantly improved (p <0.0001); the regression analysis found a negative association between TF-BUT changes and age at baseline and at month 6 (r = -0.32; p = 0.0082 and r = -0.31; p = 0.0085). Patients with no corneal fluorescein staining statistically increased after substitution (p = 0.04). Quality of life as examined by the GSS symptoms (SYMP) score statistically improved (p <0.0001), revealing an association between GSS SYMP score and age [coefficient -0.67, 95% confidence interval (CI) -1.13 to -0.21, p = 0.0005), superficial keratitis (coefficient -8.26, 95% CI -15.73 to -0.80, p = 0.031) and TF-BUT (coefficient 4.94, 95% CI 1.71 to 8.17, p = 0.003). Conclusion: Brinzolamide/timolol FC is associated with reduced topical discomfort and improved signs of ocular surface disease. The good tolerability and comfort of this FC might contribute to good patient adherence.

AB - Purpose: To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). Methods: Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pressure (IOP), tear film break-up-time (TF-BUT), fluorescein staining and Glaucoma Symptom Scale (GSS) questionnaire were recorded at baseline and after 6 months. Results: Median interquartile range (IQR) IOP was 16 (IQR 15 18) mmHg at baseline and 16 (15 17) mmHg and 6 months. TF-BUT significantly improved (p <0.0001); the regression analysis found a negative association between TF-BUT changes and age at baseline and at month 6 (r = -0.32; p = 0.0082 and r = -0.31; p = 0.0085). Patients with no corneal fluorescein staining statistically increased after substitution (p = 0.04). Quality of life as examined by the GSS symptoms (SYMP) score statistically improved (p <0.0001), revealing an association between GSS SYMP score and age [coefficient -0.67, 95% confidence interval (CI) -1.13 to -0.21, p = 0.0005), superficial keratitis (coefficient -8.26, 95% CI -15.73 to -0.80, p = 0.031) and TF-BUT (coefficient 4.94, 95% CI 1.71 to 8.17, p = 0.003). Conclusion: Brinzolamide/timolol FC is associated with reduced topical discomfort and improved signs of ocular surface disease. The good tolerability and comfort of this FC might contribute to good patient adherence.

KW - brinzolamide/timolol fixed combination

KW - efficacy

KW - glaucoma

KW - ocular surface

KW - tolerability

UR - http://www.scopus.com/inward/record.url?scp=80054058311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054058311&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.589384

DO - 10.1517/14656566.2011.589384

M3 - Article

C2 - 21679090

AN - SCOPUS:80054058311

VL - 12

SP - 2425

EP - 2431

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -